David Mountcastle, CFO of Privia Health Group (PRVA), recently sold 13,018 shares over March 12 and 13, 2026, for approximately $283,000, as disclosed in an SEC Form 4 filing. This sale, executed at a weighted average price of $21.71, reduced his direct holdings by 5.24%, leaving him with 226,804 shares, which represent 0.18% of the company’s outstanding shares. Notably, the transaction was solely for tax withholding purposes related to the vesting of performance stock units.
For investors, this sale should not raise alarms regarding PRVA’s stock performance. The CFO’s share divestiture aligns with tax obligations following the vesting of restricted and performance stock units, which is a common practice among executives. Despite a 10% decline in PRVA’s stock price in 2026, the company reported strong Q4 FY 2025 earnings, exceeding expectations with a 7-cent per share profit, and remains optimistic about growth following its recent acquisition of an Accountable Care Organization.
The key takeaway for market professionals is that while insider selling can sometimes signal trouble, in this case, Mountcastle’s transaction appears routine and tied to tax obligations, rather than indicative of broader concerns about Privia’s financial health or strategic direction.
Source: fool.com